Tearsheet

Omnicell (OMCL)

Market Price (12/29/2025): $46.385 | Market Cap: $2.1 Bil
Sector: Health Care | Industry: Health Care Technology

Omnicell (OMCL)

Market Price (12/29/2025): $46.385
Market Cap: $2.1 Bil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%	Trading close to highs Dist 52W High is -0.9%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 123x, P/EPrice/Earnings or Price/(Net Income) is 106x
1	Low stock price volatility Vol 12M is 43%	Weak multi-year price returns 2Y Excs Rtn is -27%, 3Y Excs Rtn is -85%	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0%
2	Megatrend and thematic drivers Megatrends include Automation & Robotics, and Digital Health & Telemedicine. Themes include Process / Warehouse Automation, AI in Healthcare Management, Show more.		Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2%
3			Key risks OMCL key risks include [1] a dependence on a limited number of suppliers for critical components and technology, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%
1	Low stock price volatility Vol 12M is 43%
2	Megatrend and thematic drivers Megatrends include Automation & Robotics, and Digital Health & Telemedicine. Themes include Process / Warehouse Automation, AI in Healthcare Management, Show more.
3	Trading close to highs Dist 52W High is -0.9%
4	Weak multi-year price returns 2Y Excs Rtn is -27%, 3Y Excs Rtn is -85%
5	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 123x, P/EPrice/Earnings or Price/(Net Income) is 106x
6	Weak revenue growth Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.2%
8	Key risks OMCL key risks include [1] a dependence on a limited number of suppliers for critical components and technology, Show more.

Valuation, Metrics & Events

	12/29/25	2024	2023	2022	2021
Share Price CYE	$46.38	$44.52	$37.63	$50.42	$180.44
Market Cap CYE ($ Bil)	2.1	2.1	1.7	2.3	7.9
Total Debt ($ Bil)	0.2	0.4	0.6	0.6	0.5
Total Cash ($ Bil)	0.2	0.4	0.5	0.3	0.4
Enterprise Value ($ Bil)	2.1	2.5	2.3	2.9	8.4
Valuation Ratios
P/S TTM	1.8	1.8	1.5	1.7	6.9
P/EBIT TTM	123.2	6,083.1	-48.8	-963.6	87.6
P/E TTM	106.0	163.6	-83.5	396.3	100.8
P/FCF TTM	22.5	15.2	13.5	131.4	45.2
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/29/25	2024	2023
Share Price CYE	$46.38	$44.52	$37.63
Market Cap CYE ($ Bil)	2.1	2.1	1.7
Total Debt ($ Bil)	0.2	0.4	0.6
Total Cash ($ Bil)	0.2	0.4	0.5
Enterprise Value ($ Bil)	2.1	2.5	2.3
Valuation Ratios
P/S TTM	1.8	1.8	1.5
P/EBIT TTM	123.2	6,083.1	-48.8
P/E TTM	106.0	163.6	-83.5
P/FCF TTM	22.5	15.2	13.5
Sector Ratios
P/S TTM (Sector)	4.4	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	OMCL	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	1.2
Rev Chg Q	10.0%	7.3%
Rev Chg LTM	10.7%	6.1%
Rev Chg 3Y Avg	-3.0%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	0.0
CFO LTM ($ Bil)	0.2
Net Inc LTM ($ Bil)	0.0
Op Mgn LTM	1.5%	18.8%
CFO/Rev LTM	13.0%	20.4%
Net Inc Mgn	1.7%	13.1%
VALUATION	MODERATE
P/S	1.8	3.3
P/CFO	13.8	15.8
P/FCF	22.5	20.7
P/E	106.0	23.7
STABILITY	GOOD
Debt/Equity	0.10	0.21
Cash/Assets	0.10	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Annual Recurring Revenue (ARR)	An expected range of $610 million to $630 million for year-end 2025.	10302025	Link
Product Backlog	$647 million	12312024	Link
Product Bookings	An anticipated range of $500 million to $550 million for the full year 2025.	2062025	Link
Recurring Revenue as a Percentage of Total Revenue	56%	5062025	Link
Installed Base	More than one-half of the top 300 U.S. health systems.	10302025	Link

Upcoming
2/05/2026	Earnings Release	Rev: - EPS: -

OMCL Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

The stock of Omnicell (OMCL) experienced a 42.4% movement during the approximate period from August 31, 2025, to December 29, 2025, driven by several key factors.

1. Strong Third Quarter 2025 Financial Results and Raised Guidance: Omnicell reported robust financial performance for the third quarter of 2025, surpassing analyst expectations for both revenue and adjusted earnings per share. Revenue reached $310.6 million, a 10% increase year-over-year, and non-GAAP earnings per share were $0.51, significantly higher than the estimated $0.36. This strong beat led to an immediate positive reaction in the stock, with shares rising approximately 8.2% in pre-market trading on October 30, 2025. The company also raised its full-year 2025 guidance for total revenues and adjusted earnings per share, reinforcing investor confidence in its future growth trajectory.

2. Increased Analyst Optimism and Upward Earnings Estimate Revisions: Analysts showed growing optimism regarding Omnicell's earnings prospects, leading to solid improvement in earnings estimates. The consensus estimate for the current year saw an increase of 8.84%, with two estimates moving higher over the past month (as of November 3, 2025), and no negative revisions. This positive trend in earnings estimate revisions often correlates with near-term stock price movements, further contributing to the stock's momentum.

Show more

Stock Movement Drivers

Fundamental Drivers

The 51.0% change in OMCL stock from 9/28/2025 to 12/28/2025 was primarily driven by a 70.4% change in the company's P/E Multiple.

	9282025	12282025	Change
Stock Price ($)	30.72	46.40	51.04%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	1149.53	1177.74	2.45%
Net Income Margin (%)	2.01%	1.69%	-15.79%
P/E Multiple	62.25	106.08	70.39%
Shares Outstanding (Mil)	46.79	45.54	2.67%
Cumulative Contribution			50.93%

LTM = Last Twelve Months as of date shown

Market Drivers

9/28/2025 to 12/28/2025

	Return	Correlation
OMCL	51.0%
Market (SPY)	4.3%	6.8%
Sector (XLV)	15.2%	8.2%

Fundamental Drivers

The 57.9% change in OMCL stock from 6/29/2025 to 12/28/2025 was primarily driven by a 64.1% change in the company's P/E Multiple.

	6292025	12282025	Change
Stock Price ($)	29.38	46.40	57.93%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	1135.76	1177.74	3.70%
Net Income Margin (%)	1.87%	1.69%	-9.32%
P/E Multiple	64.62	106.08	64.15%
Shares Outstanding (Mil)	46.60	45.54	2.27%
Cumulative Contribution			57.85%

LTM = Last Twelve Months as of date shown

Market Drivers

6/29/2025 to 12/28/2025

	Return	Correlation
OMCL	57.9%
Market (SPY)	12.6%	21.1%
Sector (XLV)	17.0%	12.1%

Fundamental Drivers

The 5.3% change in OMCL stock from 12/28/2024 to 12/28/2025 was primarily driven by a 10.7% change in the company's Total Revenues ($ Mil).

	12282024	12282025	Change
Stock Price ($)	44.06	46.40	5.31%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	1064.21	1177.74	10.67%
P/S Multiple	1.91	1.79	-6.10%
Shares Outstanding (Mil)	46.15	45.54	1.33%
Cumulative Contribution			5.29%

LTM = Last Twelve Months as of date shown

Market Drivers

12/28/2024 to 12/28/2025

	Return	Correlation
OMCL	5.3%
Market (SPY)	17.0%	40.2%
Sector (XLV)	13.8%	31.3%

Fundamental Drivers

The -5.6% change in OMCL stock from 12/29/2022 to 12/28/2025 was primarily driven by a -53.9% change in the company's Net Income Margin (%).

	12292022	12282025	Change
Stock Price ($)	49.17	46.40	-5.63%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	1309.31	1177.74	-10.05%
Net Income Margin (%)	3.67%	1.69%	-53.90%
P/E Multiple	45.49	106.08	133.19%
Shares Outstanding (Mil)	44.44	45.54	-2.47%
Cumulative Contribution			-5.69%

LTM = Last Twelve Months as of date shown

Market Drivers

12/29/2023 to 12/28/2025

	Return	Correlation
OMCL	23.3%
Market (SPY)	48.4%	21.9%
Sector (XLV)	17.8%	24.9%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
OMCL Return	47%	50%	-72%	-25%	18%	3%	-44%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
OMCL Win Rate	58%	58%	25%	50%	42%	50%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
OMCL Max Drawdown	-32%	-2%	-74%	-42%	-32%	-45%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See OMCL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	OMCL	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-84.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	528.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-38.6%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	62.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	230 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-26.4%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	35.9%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	147 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-78.0%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	353.7%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	2,068 days	1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

Omnicell's stock fell -84.1% during the 2022 Inflation Shock from a high on 11/23/2021. A -84.1% loss requires a 528.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Omnicell (OMCL)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

AI Analysis | Feedback

Here are two analogies to describe Omnicell:

Toast for hospital medication management: Just as Toast provides integrated hardware and software systems to streamline operations for restaurants, Omnicell offers comprehensive technology solutions, including automated dispensing cabinets and software, to manage and optimize medication workflows in hospitals.
Zebra Technologies for hospital pharmacies: Similar to how Zebra Technologies provides hardware and software for tracking assets, managing inventory, and improving operational efficiency across various industries, Omnicell specializes in technology that automates and intelligently manages medication inventory and distribution specifically within hospital pharmacies and care settings.

AI Analysis | Feedback

Automated Medication Dispensing Systems: Hardware solutions like automated cabinets and carts that securely store and dispense medications within healthcare facilities.
Medication Inventory & Workflow Management Software: Cloud-based and on-premise software platforms that optimize medication tracking, ordering, and pharmacy operational workflows.
Point-of-Care Medication Management: Integrated solutions providing secure, efficient access to medications for clinicians directly at the patient's bedside or other care locations.
Medication Adherence Solutions: Products and services designed to assist patients in managing their medication regimens at home, thereby improving adherence and health outcomes.
Sterile Compounding Automation: Technology and services that automate and enhance the safety and efficiency of preparing sterile medications in hospital pharmacies.

AI Analysis | Feedback

Omnicell (OMCL) primarily sells its medication management solutions and adherence tools to other companies and healthcare organizations, operating on a business-to-business (B2B) model.

Omnicell's customer base is diverse, and the company does not publicly disclose specific major customer companies by name in its SEC filings. This is because its revenue is derived from a broad range of healthcare providers, and no single customer or small group of customers accounts for a significant portion of its revenue (typically 10% or more) that would necessitate individual disclosure.

Instead, Omnicell serves various types of healthcare organizations, including:

Hospitals and Health Systems: This category includes acute care hospitals, integrated delivery networks (IDNs), and multi-hospital systems. These organizations utilize Omnicell's automated dispensing systems, medication inventory management, and analytics solutions to enhance medication safety and efficiency within their facilities.
Retail Pharmacies: Both independent and chain pharmacies are customers, leveraging Omnicell's solutions for central fill, robotic dispensing, and medication synchronization to improve operational efficiency, reduce costs, and support patient adherence programs.
Long-Term Care Facilities and Other Care Settings: Omnicell provides solutions to skilled nursing facilities, assisted living centers, and other post-acute care providers, helping them manage medications, ensure compliance, and improve patient safety in these environments.

AI Analysis | Feedback

null

AI Analysis | Feedback

Here is the management team of Omnicell (OMCL):

Randall Lipps, Chairman, President, Chief Executive Officer, and Founder

Randall Lipps founded Omnicell in 1992, inspired by inefficiencies he observed in medical supply management during his daughter's hospitalization. Under his leadership, Omnicell became a publicly traded company in August 2001 and has grown to offer a comprehensive portfolio of medication management solutions. Prior to founding Omnicell, he was Assistant Vice President of Sales and Operations for a division of American Airlines. He also served as a director for Invuity, Inc. from 2013 to 2018.

Baird Radford, Executive Vice President and Chief Financial Officer

Baird Radford joined Omnicell as Executive Vice President and Chief Financial Officer in August 2025, bringing over 30 years of experience in healthcare and technology finance. He previously served as Chief Financial Officer for Allakos Inc., a biotechnology company. Before that, he was Senior Vice President of Finance for Aimmune Therapeutics Inc., which was acquired by Nestle Health Science in late 2020. Radford also held the CFO position at HeartFlow, Inc., an AI health-tech company, where he managed finance and investor relations and raised significant capital. His career also includes leadership roles at Intuitive Surgical, Inc., eBay, Inc., and PricewaterhouseCoopers.

Nnamdi Njoku, Executive Vice President and Chief Operating Officer

Nnamdi Njoku joined Omnicell in October 2024, bringing over 25 years of experience in leading global operations within the healthcare and medical technology sectors. Before joining Omnicell, he served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc. Prior to Zimmer Biomet, Mr. Njoku spent over 18 years in various executive leadership roles at Medtronic plc, including Senior Vice President and President for the Neuromodulation Operating Unit. His background also includes operational and consulting roles at UnitedHealth Group and Deloitte Consulting.

Perry Genova, Senior Vice President, Chief Technology Officer

Perry A. Genova, PhD, joined Omnicell as Senior Vice President, Chief Technology Officer in March 2025. He is an industry thought leader with an extensive background in innovation, growth, and value delivery. His previous roles include Senior Vice President of Research and Development at EndoQuest Robotics and Titan Medical USA, President and CEO at Centauri Robotic Surgical Systems and Oncoscope, and Vice President at GlaxoSmithKline and Kos Pharmaceuticals. Notably, he built an $800 million division at Kos Pharmaceuticals and holds 58 issued U.S. patents.

Corey Manley, Executive Vice President, Chief Legal and Administrative Officer

Corey Manley joined Omnicell in April 2021 as Executive Vice President, Chief Legal and Administrative Officer. He has over 20 years of experience as a legal and business advisor to global technology and healthcare technology companies. Before Omnicell, he was Chief Legal Officer, Corporate Secretary, and Chief Compliance Officer with a global fintech company. He also served as a Partner in the law firms of Kirkland & Ellis and Duane Morris and began his career as an engineer at Motorola.

AI Analysis | Feedback

The key risks to Omnicell's business include:

Competitive Market and Economic Pressures: Omnicell operates in a highly competitive healthcare automation market, characterized by continuous innovation from both new and existing players. The company faces economic pressures such as rising drug costs, healthcare consolidation, increasing cost pressures, buyer consolidation, and commoditization, which can negatively impact its pricing power, market share, and overall growth trajectory.
Regulatory and Cybersecurity Risks: Omnicell is subject to stringent healthcare, privacy, and data protection laws and regulations. Non-compliance with these regulations can lead to significant liabilities. Furthermore, the company faces substantial cybersecurity risks, including data breaches and cyber-attacks on its information technology systems and solutions, which could harm its reputation, operational continuity, and financial performance.
Dependence on a Limited Number of Suppliers: Omnicell relies on a restricted number of suppliers for specific components, equipment, raw materials, and third-party technologies. This dependence exposes the company to the risk of supply chain disruptions, which could impede its ability to meet customer demands and maintain service levels, particularly during periods of global shortages or price fluctuations.

AI Analysis | Feedback

null

AI Analysis | Feedback

Omnicell (OMCL) operates within several significant addressable markets related to healthcare automation and medication management.

The company itself highlights a total addressable market (TAM) exceeding $90 billion. This estimate, as of May 2022, encompasses the United States, UK&I, Germany, France, Spain, the Kingdom of Saudi Arabia, and Australia/New Zealand, indicating a broad global reach for their solutions.

Omnicell's main products and services include medication management solutions (such as automated dispensing cabinets, pharmacy robotics, software, and adherence tools), IV compounding solutions, and healthcare inventory management.

Here are the addressable market sizes for Omnicell's key product and service categories:

Medication Management Systems: The global medication management system market was estimated at USD 7.8 billion in 2024 and is projected to reach USD 18.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.8%. North America is a dominant region within this market, accounting for over 44.5% share and a revenue of USD 3.5 billion in 2024, with projections to reach USD 15.0 billion by 2032.
Healthcare Inventory Management: The global healthcare inventory management market size was valued at USD 22.1 billion in 2023 and is projected to reach USD 31.1 billion by 2031, with a CAGR of 5.4% from 2024 to 2031. More specifically, the global healthcare inventory management software market was valued at USD 2.43 billion in 2024 and is expected to grow to USD 5 billion by 2035, exhibiting a CAGR of 6.8% between 2025 and 2035. North America held the largest share of this market in 2023.
IV Compounding Solutions/Automation: The global IV compounding automation market size reached USD 1.84 billion in 2024 and is expected to expand at a CAGR of 8.7% from 2025 to 2033, reaching USD 3.89 billion by 2033. Another report estimated the global IV compounding devices market to reach USD 2.5 billion by 2025, with a CAGR of 12% through 2033. The Intravenous Solution Compounders Market, which includes automated solutions, is estimated to be valued at USD 2.7 billion globally in 2025 and is projected to reach USD 4.9 billion by 2035, with a CAGR of 6.3%. In the U.S. specifically, the intravenous solution compounders market is estimated at USD 914.4 million in 2025, anticipated to reach USD 1.5 billion by 2035. The overall U.S. intravenous solutions market was estimated at USD 5.03 billion in 2024 and is projected to grow to USD 7.91 billion by 2030, at a CAGR of 7.8% from 2025 to 2030.

These market sizes demonstrate substantial and growing opportunities for Omnicell's offerings within the healthcare technology sector.

AI Analysis | Feedback

Here are the expected drivers of future revenue growth for Omnicell (OMCL) over the next 2-3 years:

Growth in Point-of-Care Connected Devices: Omnicell anticipates continued strong demand for its point-of-care connected devices, including products like XT Amplify and XTExtend. This segment has been a core driver for product revenue and overall performance, with strong customer wins with major health systems and government healthcare facilities.
Expansion of SaaS and Expert Services: The company is focused on driving growth in its subscription-based SaaS (Software as a Service) and Expert Services. These services contribute to annual recurring revenue, leverage established customer relationships, and expand Omnicell's total addressable market (TAM) by catering to the increasing need for provider digitization and an evolving medication supply chain.
Advancement of Intelligent Medication Management and Autonomous Pharmacy Vision: Omnicell is strategically transforming into an intelligent medication management technology company. This includes the development and adoption of the OmniSphere cloud-based platform, designed to integrate robotics and smart devices for data-driven medication management, ultimately moving closer to the industry's vision of an Autonomous Pharmacy.
Market Share Gains and Deep Customer Relationships: Omnicell maintains strong relationships with over half of the top 300 U.S. health systems, providing significant opportunities for expansion within its existing customer base and potential market share gains from competitors.
Continued Innovation and New Solutions: The company emphasizes ongoing innovation and investment in new products and solutions, such as the MedTrack RFID Line, to deliver outcomes-centric solutions and drive long-term sustainable growth. These efforts are expected to continually improve the customer experience and deliver value.

AI Analysis | Feedback

Share Repurchases

Omnicell authorized a new $75 million stock repurchase program in May 2025, which was substantially completed in the third quarter of 2025 with approximately $62 million in repurchases.
The company repurchased approximately $74.92 million of shares in 2025 under an ongoing buyback program.
Omnicell repurchased approximately $52.2 million of its common stock in 2022 and $53.0 million in 2020.

Share Issuance

In September 2020, Omnicell priced a $500 million private placement of 0.25% Convertible Senior Notes due 2025, yielding approximately $486.5 million in net proceeds.
In 2025, the company completed a private offering of $172.5 million in 1.00% Convertible Senior Notes due 2029.

Inbound Investments

No information available.

Outbound Investments

In October 2025, Omnicell acquired ANiGENT, LLC, a software company specializing in drug diversion detection.
In January 2022, Omnicell acquired pharmacy software solutions provider MarkeTouch Media for $82 million in cash.
Omnicell also acquired Hub and Spoke Innovations Limited in January 2022, which distributes the Pharmaself24 prescription collection kiosk.

Capital Expenditures

Omnicell's capital allocation has been focused on its "Autonomous Pharmacy" vision, encompassing investments in robotics, smart devices, intelligent software, and expert services to optimize medication management.
Investments are aimed at developing new products and solutions, accelerating growth in recurring revenue, and expanding cloud-based offerings.

Better Bets than Omnicell (OMCL)

Waystar

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for OMCL: -3.0% | 1.8x)

UNH (11.4% | 0.7x)

UnitedHealth

HCA (6.6% | 1.6x)

HCA Healthcare

MCK (12.6% | 0.3x)

McKesson

CVS (7.7% | 0.3x)

CVS Health

ELV (8.4% | 0.4x)

Elevance Health

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for OMCL: -3.0% | 123.3x)

LLY (23.4% | 42.3x)

Eli Lilly

JNJ (6.1% | 20.7x)

Johnson & Johnson

ABBV (1.2% | 28.3x)

AbbVie

UNH (11.4% | 11.4x)

UnitedHealth

MRK (2.9% | 11.9x)

Merck

Higher Rev Chg LTM (Value for OMCL: 10.7%)

LLY (36.8%)

Eli Lilly

ISRG (22.2%)

Intuitive Surgical

BSX (21.6%)

Boston Scientific

MCK (17.2%)

McKesson

SYK (11.0%)

Stryker

Higher Rev Chg 3Y Avg (Value for OMCL: -3.0%)

LLY (23.4%)

Eli Lilly

UNH (11.4%)

UnitedHealth

JNJ (6.1%)

Johnson & Johnson

MRK (2.9%)

Merck

ABBV (1.2%)

AbbVie

Higher Op Mgn LTM (Value for OMCL: 1.5%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

ABBV (24.1%)

AbbVie

UNH (6.1%)

UnitedHealth

Higher CFO/Rev LTM (Value for OMCL: 13.0%)

ABBV (35.0%)

AbbVie

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

LLY (20.5%)

Eli Lilly

TMO (17.5%)

Thermo Fisher Scientific

Higher FCF/Rev LTM (Value for OMCL: 8.0%)

ABBV (33.0%)

AbbVie

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

ABT (15.8%)

Abbott Laboratories

TMO (14.0%)

Thermo Fisher Scientific

Higher Total Yield (Value for OMCL: 0.9%)

MRK (10.2%)

Merck

UNH (8.5%)

UnitedHealth

JNJ (7.5%)

Johnson & Johnson

ABBV (3.4%)

AbbVie

Apple

NVDA (2.2%)

NVIDIA

		Best Bets In Health Care Sector
	OMCL	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	106.1	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	123.3	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	10.0%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	10.7%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	-3.0%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	11.0%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Omnicell Earnings Notes
2	Omnicell Stock Jump Looks Great, But How Secure Is That Gain?	Return
3	OMCL Dip Buy Analysis
4	Omnicell Total Shareholder Return (TSR): 18.3% in 2024 and -37.3% 3-yr compounded annual returns (below peer average)
5	Omnicell (OMCL) Operating Cash Flow Comparison	Financials
6	Omnicell (OMCL) Net Income Comparison	Financials
7	Omnicell (OMCL) Operating Income Comparison	Financials
8	Omnicell (OMCL) Revenue Comparison	Financials
9	Omnicell Market Price	Market Price
10	Omnicell vs. S&P500 Correlation	Correlation

	Title
0	ARTICLES

Trade Ideas

Select ideas related to OMCL. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for Omnicell

Peers to compare with:

Financials

	OMCL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Omnicell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	46.40	23.26	24.49	305.09	78.16	273.40	62.28
Mkt Cap	2.1	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	1,178	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	17	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	94	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	126	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	153	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	183	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	OMCL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Omnicell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	10.7%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	-3.0%	-3.9%	6.5%	2.6%	3.7%	1.8%	2.2%
Rev Chg Q	10.0%	4.2%	14.4%	9.1%	7.5%	9.6%	9.4%
QoQ Delta Rev Chg LTM	2.5%	1.1%	3.7%	2.1%	1.8%	2.1%	2.1%
Op Mgn LTM	1.5%	6.6%	4.8%	17.7%	22.5%	31.9%	12.1%
Op Mgn 3Y Avg	-2.0%	7.4%	7.2%	16.4%	24.2%	30.8%	11.9%
QoQ Delta Op Mgn LTM	0.1%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.1%
CFO/Rev LTM	13.0%	6.7%	8.5%	20.6%	23.8%	26.6%	16.8%
CFO/Rev 3Y Avg	16.0%	6.8%	12.7%	21.4%	26.1%	28.4%	18.7%
FCF/Rev LTM	8.0%	5.1%	1.8%	18.1%	22.1%	23.5%	13.0%
FCF/Rev 3Y Avg	11.0%	5.5%	4.6%	18.6%	24.6%	25.6%	14.8%

Valuation

	OMCL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Omnicell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	2.1	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	1.8	0.4	1.0	4.4	5.4	10.0	3.1
P/EBIT	123.3	6.8	19.9	25.1	22.5	31.3	23.8
P/E	106.1	8.6	572.7	36.0	29.9	41.0	38.5
P/CFO	13.8	5.9	11.2	21.1	22.5	37.5	17.5
Total Yield	0.9%	14.1%	2.3%	5.0%	5.4%	2.8%	3.9%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	6.9%	10.6%	5.5%	6.4%	6.0%	3.1%	6.2%
D/E	0.1	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	0.0	0.3	0.6	0.2	0.0	0.0	0.1

Returns

	OMCL	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	Omnicell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	27.1%	-3.6%	12.7%	-1.1%	1.6%	-2.0%	0.2%
3M Rtn	51.0%	-11.9%	2.7%	7.9%	17.0%	7.1%	7.5%
6M Rtn	57.9%	-4.0%	34.5%	6.6%	15.2%	36.3%	24.9%
12M Rtn	5.3%	-27.0%	16.2%	40.5%	34.5%	7.5%	11.8%
3Y Rtn	-5.6%	-3.7%	67.3%	141.3%	79.6%	114.1%	73.5%
1M Excs Rtn	23.0%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	46.7%	-16.2%	-1.7%	3.6%	12.7%	2.8%	3.2%
6M Excs Rtn	45.7%	-16.3%	22.3%	-5.7%	3.0%	24.0%	12.6%
12M Excs Rtn	-11.7%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	-4.6%
3Y Excs Rtn	-84.9%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

Comparison Analyses

	Title
0	Why OMCL With 3.1% Upside May Beat CAH?
1	Omnicell vs. Becton Dickinson and company: With Return Forecast Of 34%, Becton Dickinson and company Is A Better Bet
2	Omnicell vs. National Instruments: With Return Forecast Of 19%, Omnicell Is A Better Bet
3	Omnicell vs. Texas Roadhouse: With Return Forecast Of 34%, Texas Roadhouse Is A Better Bet
4	Omnicell vs. Flowers Foods: With Return Forecast Of 28%, Omnicell Is A Better Bet
5	Omnicell vs. Penn National Gaming: With Return Forecast Of 53%, Penn National Gaming Is A Better Bet
6	Omnicell vs. Cerner: With Return Forecast Of 24%, Omnicell Is A Better Bet
7	Omnicell vs. HubSpot: With Return Forecast Of 42%, HubSpot Is A Better Bet
8	Omnicell vs. Verisign CA: With Return Forecast Of 13%, Omnicell Is A Better Bet
9	Omnicell vs. Enphase Energy: With Return Forecast Of 13%, Omnicell Is A Better Bet

FDIC Bank Data

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/5/2025	2/27/2025	2/28/2024	3/1/2023	2/25/2022	2/24/2021	2/26/2020
Key Financials
Total Revenue	1,178	1,112	1,147	1,296	1,132	892	897
EBITDA	104	90	61	97	174	107	142
Operating Income	17	0	-35	-2	90	36	78
Net Income	20	13	-20	6	78	32	61
EPS	0.43	0.27	-0.45	0.13	1.79	0.76	1.48
Growth Rates
Total Revenue Growth	10.7%	-3.0%	-11.5%	14.5%	26.9%	-0.5%	13.9%
EBITDA Growth	86.6%	48.4%	-37.3%	-44.5%	62.8%	-24.8%	48.8%
Operating Income Growth	148.4%	101.0%	-1401.0%	-102.6%	151.9%	-54.7%	76.5%
Net Income Growth	212.6%	161.5%	-460.7%	-92.7%	141.8%	-47.5%	62.6%
Margins
EBITDA Margin	8.8%	8.1%	5.3%	7.5%	15.4%	12.0%	15.9%
Operating Income Margin	1.5%	0.0%	-3.0%	-0.2%	7.9%	4.0%	8.7%
Net Income Margin	1.7%	1.1%	-1.8%	0.4%	6.9%	3.6%	6.8%
Cash & Debt
Total Cash	193	382	480	342	360	496	137
Total Debt	207	383	614	617	541	528	111
Net Debt / (Cash)	13	1	134	275	181	32	-26
Cash Flows
Net Cash from Operations	153	188	181	78	232	186	145
Free Cash from Operations	94	135	126	17	173	131	83
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	62	-0	-0	52	-0	53	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/5/2025	8/6/2025	5/7/2025	2/27/2025	11/8/2024	8/6/2024	5/7/2024	2/28/2024	11/3/2023	8/4/2023	5/5/2023	3/1/2023
Key Financials Quarterly
Total Revenue	311	291	270	307	282	277	246	259	299	299	291	298
Ebitda	30	30	10	35	28	26	1	0	27	32	1	-14
Operating Income	8	8	-12	12	7	3	-22	-23	4	8	-23	-38
Net Income	5	6	-7	16	9	4	-16	-14	6	3	-15	-28
EPS	0.12	0.12	-0.15	0.34	0.19	0.08	-0.34	-0.32	0.12	0.08	-0.33	-0.64
Key Financials TTM
Total Revenue TTM	1,178	1,150	1,136	1,112	1,064	1,080	1,103	1,147	1,186	1,235	1,268	1,296
Ebitda TTM	104	103	99	90	56	55	61	61	47	63	69	97
Operating Income TTM	17	15	11	0	-35	-38	-34	-35	-50	-35	-30	-2
Net Income TTM	20	23	21	13	-18	-21	-21	-20	-34	-23	-18	6
Growth Rates Quarterly
Total Revenue Growth	10.0%	5.0%	9.6%	18.6%	-5.4%	-7.4%	-15.3%	-13.0%	-14.2%	-9.8%	-8.8%	-4.3%
EBITDA Growth	5.3%	14.3%	665.1%	9539.6%	3.1%	-18.2%	6.1%	102.6%	-36.9%	-16.0%	-95.7%	-139.7%
Operating Income Growth	25.6%	151.9%	46.8%	153.1%	76.8%	-58.4%	4.9%	39.1%	-79.9%	-37.9%	-551.7%	-431.0%
Net Income Growth	-36.7%	51.0%	55.2%	210.2%	55.4%	8.2%	-4.5%	49.4%	-66.9%	-61.9%	-282.6%	-303.2%
Margins Quarterly
EBITDA Margin	9.5%	10.2%	3.8%	11.3%	10.0%	9.4%	0.5%	0.1%	9.1%	10.6%	0.4%	-4.6%
Operating Income Margin	2.7%	2.8%	-4.3%	4.0%	2.3%	1.2%	-8.9%	-9.0%	1.2%	2.6%	-7.9%	-12.9%
Net Income Margin	1.8%	1.9%	-2.6%	5.2%	3.1%	1.3%	-6.4%	-5.6%	1.9%	1.2%	-5.2%	-9.5%
Cash & Debt
Total Cash	193	412	399	382	582	569	524	480	458	411	351	342
Total Debt	207	384	386	383	614	615	616	614	612	615	615	617
Net Debt / (Cash)	13	-27	-14	1	32	46	91	134	154	204	264	275
Cash Flows Quarterly
FCF from Operations	28	43	26	56	23	59	50	38	57	73	13	82
Cash Flows TTM
FCF from Operations TTM	153	148	164	188	170	204	218	181	225	189	107	78
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	62	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	3.9%	3.2%	-5.9%	5.8%	3.2%	1.0%	-12.1%	-11.0%	1.7%	1.3%	-8.8%	-17.0%
Return on Invested Capital (ROIC) TTM
ROIC TTM	2.1%	1.8%	1.1%	0.0%	-5.8%	-6.4%	-5.3%	-5.3%	-6.9%	-4.3%	-2.5%	-0.3%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Connected devices, software licenses, and other	624	828	739	560	574
Technical services	226	207	207	202	194
Software as a Service (SaaS) and Expert Services	213	186	113	54	43
Consumables	85	75	73	76	86
Total	1,147	1,296	1,132	892	897

Price Behavior

Price Behavior

Market Price	$46.40
Market Cap ($ Bil)	2.1
First Trading Date	08/09/2001
Distance from 52W High	-0.9%
	50 Days	200 Days
DMA Price	$37.42	$32.37
DMA Trend	indeterminate	up
Distance from DMA	24.0%	43.4%
	3M	1YR
Volatility	45.0%	43.5%
Downside Capture	-128.67	89.24
Upside Capture	96.51	80.32
Correlation (SPY)	7.2%	40.4%

OMCL Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.04	0.41	0.68	1.02	0.89	0.87
Up Beta	1.87	1.20	1.48	1.61	0.91	0.97
Down Beta	0.34	1.24	0.26	0.86	0.90	0.91
Up Capture	163%	62%	89%	98%	57%	34%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	10	21	32	64	119	361
Down Capture	57%	-69%	52%	87%	104%	99%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	10	21	31	60	127	385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of OMCL With Other Asset Classes (Last 1Y)
	OMCL	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	3.2%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.2%
Annualized Volatility	43.4%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	0.19	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		31.1%	39.6%	-5.8%	6.6%	33.5%	16.1%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of OMCL With Other Asset Classes (Last 5Y)
	OMCL	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-16.7%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	48.2%	14.5%	17.1%	15.5%	18.7%	18.9%	48.6%
Sharpe Ratio	-0.21	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		28.8%	34.1%	5.6%	5.3%	35.9%	17.2%

Based On 10-Year Data

		Comparison of OMCL With Other Asset Classes (Last 10Y)
	OMCL	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	4.8%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	42.8%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.26	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		38.1%	41.0%	2.5%	12.9%	36.9%	15.2%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	2,735,718
Short Interest: % Change Since 11302025	12.8%
Average Daily Volume	630,456
Days-to-Cover Short Interest	4.34
Basic Shares Quantity	45,540,000
Short % of Basic Shares	6.0%

Returns Analyses

	Title
0	Omnicell Stock Jump Looks Great, But How Secure Is That Gain?
1	Omnicell Stock Return Comparison
2	[10/14/2021] Omnicell (OMCL) Stock Price Forecast: AI Forecasts OMCL Stock Price To Be Around $163.20 In A Month (Up 3.4%)
3	Omnicell (OMCL) Stock Return: AI Predicts OMCL Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
10/30/2025	13.6%	20.9%	22.2%
7/31/2025	4.4%	4.7%	12.1%
5/6/2025	-15.8%	-9.9%	2.6%
2/6/2025	-11.2%	-8.8%	-16.7%
10/30/2024	32.2%	24.1%	20.8%
8/1/2024	33.0%	33.7%	54.9%
5/2/2024	7.8%	10.3%	19.9%
2/8/2024	-10.4%	-14.6%	-12.0%
...
SUMMARY STATS
# Positive	12	12	12
# Negative	11	11	11
Median Positive	4.8%	4.6%	10.7%
Median Negative	-6.6%	-9.9%	-7.4%
Max Positive	33.0%	33.7%	54.9%
Max Negative	-34.5%	-36.7%	-33.3%

	Forward Returns
10/30/2025	13.6%	20.9%	22.2%
7/31/2025	4.4%	4.7%	12.1%
5/6/2025	-15.8%	-9.9%	2.6%
2/6/2025	-11.2%	-8.8%	-16.7%
10/30/2024	32.2%	24.1%	20.8%
8/1/2024	33.0%	33.7%	54.9%
5/2/2024	7.8%	10.3%	19.9%
2/8/2024	-10.4%	-14.6%	-12.0%
11/2/2023	-18.3%	-13.6%	-5.5%
8/1/2023	4.7%	4.2%	-6.7%
2/28/2023	5.0%	-1.4%	2.0%
11/2/2022	-34.5%	-36.7%	-33.3%
8/4/2022	-1.4%	-1.4%	-10.0%
4/28/2022	1.6%	4.6%	5.2%
2/14/2022	-5.5%	-15.3%	-7.4%
11/2/2021	0.5%	3.0%	1.1%
7/29/2021	-4.3%	0.7%	4.4%
4/29/2021	0.8%	-2.8%	-3.4%
1/13/2021	-2.6%	1.5%	9.3%
10/27/2020	0.5%	4.6%	24.8%
7/28/2020	5.4%	-0.9%	-2.7%
5/7/2020	-6.6%	-17.3%	-1.8%
2/6/2020	-1.8%	3.3%	-7.9%
SUMMARY STATS
# Positive	12	12	12
# Negative	11	11	11
Median Positive	4.8%	4.6%	10.7%
Median Negative	-6.6%	-9.9%	-7.4%
Max Positive	33.0%	33.7%	54.9%
Max Negative	-34.5%	-36.7%	-33.3%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
09/30/2025	11/05/2025	10-Q (09/30/2025)
06/30/2025	08/06/2025	10-Q (06/30/2025)
03/31/2025	05/07/2025	10-Q (03/31/2025)
12/31/2024	02/27/2025	10-K (12/31/2024)
09/30/2024	11/08/2024	10-Q (09/30/2024)
06/30/2024	08/06/2024	10-Q (06/30/2024)
03/31/2024	05/07/2024	10-Q (03/31/2024)
12/31/2023	02/28/2024	10-K (12/31/2023)
09/30/2023	11/03/2023	10-Q (09/30/2023)
06/30/2023	08/04/2023	10-Q (06/30/2023)
03/31/2023	05/05/2023	10-Q (03/31/2023)
12/31/2022	03/01/2023	10-K (12/31/2022)
09/30/2022	11/04/2022	10-Q (09/30/2022)
06/30/2022	08/09/2022	10-Q (06/30/2022)
03/31/2022	05/09/2022	10-Q (03/31/2022)
12/31/2021	02/25/2022	10-K (12/31/2021)

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Omnicell (OMCL)

Market Price (12/29/2025): $46.385 | Market Cap: $2.1 BilSector: Health Care | Industry: Health Care Technology

Omnicell (OMCL)

Market Price (12/29/2025): $46.385Market Cap: $2.1 BilSector: Health CareIndustry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

OMCL Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Omnicell (OMCL)

Share Repurchases

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Omnicell (OMCL)

INDUSTRY: Health Care Technology

Higher Rev Chg 3Y Avg | Lower P/S (Values for OMCL: -3.0% | 1.8x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for OMCL: -3.0% | 123.3x)

Higher Rev Chg LTM (Value for OMCL: 10.7%)

Higher Rev Chg 3Y Avg (Value for OMCL: -3.0%)

Higher Op Mgn LTM (Value for OMCL: 1.5%)

Higher CFO/Rev LTM (Value for OMCL: 13.0%)

Higher FCF/Rev LTM (Value for OMCL: 8.0%)

Higher Total Yield (Value for OMCL: 0.9%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for OMCL: -3.0% | 1.8x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for OMCL: -3.0% | 123.3x)

Higher Rev Chg LTM (Value for OMCL: 10.7%)

Higher Rev Chg 3Y Avg (Value for OMCL: -3.0%)

Higher Op Mgn LTM (Value for OMCL: 1.5%)

Higher CFO/Rev LTM (Value for OMCL: 13.0%)

Higher FCF/Rev LTM (Value for OMCL: 8.0%)

Higher Total Yield (Value for OMCL: 0.9%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for OMCL: -3.0% | 1.8x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for OMCL: -3.0% | 123.3x)

Higher Rev Chg LTM (Value for OMCL: 10.7%)

Higher Rev Chg 3Y Avg (Value for OMCL: -3.0%)

Higher Op Mgn LTM (Value for OMCL: 1.5%)

Higher CFO/Rev LTM (Value for OMCL: 13.0%)

Higher FCF/Rev LTM (Value for OMCL: 8.0%)

Higher Total Yield (Value for OMCL: 0.9%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Omnicell

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Market Price (12/29/2025): $46.385 | Market Cap: $2.1 Bil
Sector: Health Care | Industry: Health Care Technology

Market Price (12/29/2025): $46.385
Market Cap: $2.1 Bil
Sector: Health Care
Industry: Health Care Technology